Breakthrough T1D applauds the authorization by the U.S. Food and Drug Administration (FDA) of the world’s first dual glucose-ketone sensing technology, for individuals ages 2 and older with diabetes. Abbott’s Libre Duo 10 Day is a two-in-one sensor that monitors both glucose and ketones and is expected to launch in the U.S. later this year.
Diabetic ketoacidosis (DKA) is one of the most common complications of T1D, and it can be life-threatening. Despite DKA being relatively common in people with T1D, studies have shown that most people with T1D do not have the tools at home to measure ketone levels. This device will give individuals with T1D a seamless way to monitor ketones before high ketone levels or symptoms develop without needing an additional device, allowing them to act earlier and prevent progression into DKA.
“In my role with Breakthrough T1D, and as someone who has lived with type 1 diabetes for decades, I understand the serious risk of diabetic ketoacidosis and how challenging it can be to identify and monitor elevated ketone levels,” said Aaron J. Kowalski, Ph.D., Chief Executive Officer of Breakthrough T1D. “New technology like Abbott’s dual glucose-ketone system has the potential to change that reality by giving people early and actionable information that can help identify and prevent dangerous complications like DKA. Breakthrough T1D is excited that the diabetes community will have this option available to support their day-to-day management.”
This milestone reflects years of Breakthrough T1D investment. Breakthrough T1D has funded research to make continuous ketone monitoring devices a reality and continues to study how they can help address ketones before they progress to DKA and mitigate the risks associated with certain adjunctive therapies, such as SGLT2 inhibitors.
Breakthrough T1D also led the first-ever international expert recommendations for use of CKM, published in The Lancet Diabetes & Endocrinology earlier this year.
Read Abbott’s announcement.
